Webcast focused on Phase II study with drug candidate CS1 in PAH

Webcast focused on Phase II study with drug candidate CS1 in PAH

Cereno’s Chief Executive Officer Sten R. Sörensen and Chief Medical Officer Dr. Björn Dahlöf is joined by Dr. Raymond Benza, Principal Investigator for the study and Dr. Philip Adamson, Vice President and Chief Medical Officer at study collaborator Abbott in this live webcast held on February 25, at 15:00 CET.

Tune in for a presentation about the background, design, and plan for the Phase II study with drug candidate CS1 in the rare disease pulmonary arterial hypertension (PAH).

Link to webcast >